Pharmaceutical Research and Manufacturers of America v. Walsh: the Supreme Court allows the states to proceed with expanding access to drugs.
نویسنده
چکیده
منابع مشابه
A New Formula for Analyzing Formulation-patent Obviousness
The generic drug industry, which is estimated to save American consumers $10 billion a year,1 owes much of its current market success to Congress’s enactment of the Hatch-Waxman Act in 1984.2 The Hatch-Waxman Act sought to achieve a delicate balance, one where Americans could obtain unprecedented access to low-cost prescription medicine without somehow undermining the incentive of brand name dr...
متن کاملThe impact of Wyeth v. Levine on FDA regulation of prescription drugs.
In Wyeth v. Levine, decided in March, 2009, the United States Supreme Court concluded that the plaintiff's failure to warn claim against the makers of the drug Phenergan was not impliedly preempted by the Food, Drug and Cosmetic Act. In doing so, the Court rejected the argument of the U.S. Food and Drug Administration (FDA) that tort claims of this nature stand as an obstacle to federal regulat...
متن کاملریسک مسؤولیت و تأثیر آن بر قیمت دارو و فراورده‌های دارویی (مطالعه تطبیقی حقوق ایران، انگلستان و آمریکا)
This study shows the effect of risk of pharmaceutical manufacturers' responsibility on the prices of medicines in the legal system in Iran, England and United State of America. By examining the type and responsibility of pharmaceutical manufacturers in these three legal systems, we concluded that in the legal system of the United State of America, acceptance of strict liability, private phar...
متن کاملThe Ftc Has a Dog in the Patent Monopoly Fight: Will Antitrust’s Bite Kill Generic Challenges?
Antitrust laws have been notoriously lenient in the patent realm, the underlying reason being that patents’ grant of exclusion create monopolies that defy antitrust laws in order to incentivize innovation. Thus, antitrust violations have rarely been found in the patent cases. But after the Supreme Court’s holding in FTC v. Actavis, brand name pharmaceutical companies may need to be more cautiou...
متن کاملPrescription data mining, medical privacy and the First Amendment: the U.S. Supreme Court in Sorrell v. IMS health Inc.
In 2011, the United States Supreme Court in Sorrell v. IMS Health Inc. struck down a Vermont law that would restrict the ability of pharmaceutical companies to purchase certain physician-identifiable prescription data without the consent of the prescriber. The law's stated purpose was threefold: to protect the privacy of medical information, to protect the public health and to contain healthcar...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Yale journal of health policy, law, and ethics
دوره 4 1 شماره
صفحات -
تاریخ انتشار 2004